The Biotechnology Innovation Organization has stated that the regulatory framework for cancer treatments is overly restrictive and may stifle innovation. A study published in the Journal of Clinical Oncology found that the regulatory framework for cancer treatments can be slow and bureaucratic, which may delay the approval of new and effective therapies.
Add the first pro or contra sub-claim
Use the buttons below to add a sub-claim or link an existing claim.
No pro sub-claims yet.
No pro sub-claims yet.
No contra sub-claims yet.